Author:
Sun Fei,Xiong Ying,Zhou Xiao-Hua,Li Qi,Xiao Lu,Long Ping,Li Lin-Jiang,Cai Mu-Yan,Wei Yan-Xing,Ma Yan-Lin,Yu Yan-Hong
Funder
Science and Technology Planning Project of Guangzhou
International Science & Technology Cooperation Program of China
State Key Development Programs of China
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, et al. Prognostic factors in stage IB–IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 2010;101:413–7.
3. Lei T, Mao W, Lei T, Dai L, Fang L, Chen W, et al. Incidence and mortality trend of cervical cancer in 11 cancer registries of China. Chin J Cancer Res. 2011;23:10–4.
4. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177–83.
5. Curtin JP, Hoskins WJ, Venkatraman ES, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol. 1996;61:3–10.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献